Compare Biocon with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs DR. REDDYS LAB - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON DR. REDDYS LAB BIOCON /
DR. REDDYS LAB
 
P/E (TTM) x 33.6 38.6 87.0% View Chart
P/BV x 4.0 5.3 75.7% View Chart
Dividend Yield % 0.2 0.5 48.9%  

Financials

 BIOCON    DR. REDDYS LAB
EQUITY SHARE DATA
    BIOCON
Mar-19
DR. REDDYS LAB
Mar-20
BIOCON /
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs7073,363 21.0%   
Low Rs5542,352 23.5%   
Sales per share (Unadj.) Rs91.91,054.2 8.7%  
Earnings per share (Unadj.) Rs16.7121.9 13.7%  
Cash flow per share (Unadj.) Rs24.2190.2 12.7%  
Dividends per share (Unadj.) Rs1.0025.00 4.0%  
Dividend yield (eoy) %0.20.9 18.1%  
Book value per share (Unadj.) Rs101.6938.7 10.8%  
Shares outstanding (eoy) m600.00166.17 361.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.92.7 253.1%   
Avg P/E ratio x37.723.4 161.0%  
P/CF ratio (eoy) x26.115.0 173.6%  
Price / Book Value ratio x6.23.0 203.8%  
Dividend payout %6.020.5 29.2%   
Avg Mkt Cap Rs m378,330474,831 79.7%   
No. of employees `0006.121.7 28.3%   
Total wages/salary Rs m11,65333,802 34.5%   
Avg. sales/employee Rs Th8,994.38,091.0 111.2%   
Avg. wages/employee Rs Th1,900.71,561.3 121.7%   
Avg. net profit/employee Rs Th1,635.3935.8 174.7%   
INCOME DATA
Net Sales Rs m55,144175,170 31.5%  
Other income Rs m1,4446,206 23.3%   
Total revenues Rs m56,588181,376 31.2%   
Gross profit Rs m15,88324,421 65.0%  
Depreciation Rs m4,47811,348 39.5%   
Interest Rs m709983 72.1%   
Profit before tax Rs m12,14018,296 66.4%   
Minority Interest Rs m90-   
Prior Period Items Rs m0561 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123-1,403 -151.3%   
Profit after tax Rs m10,02620,260 49.5%  
Gross profit margin %28.813.9 206.6%  
Effective tax rate %17.5-7.7 -228.0%   
Net profit margin %18.211.6 157.2%  
BALANCE SHEET DATA
Current assets Rs m48,228125,991 38.3%   
Current liabilities Rs m30,37672,141 42.1%   
Net working cap to sales %32.430.7 105.3%  
Current ratio x1.61.7 90.9%  
Inventory Days Days6873 93.4%  
Debtors Days Days86105 81.6%  
Net fixed assets Rs m64,13083,854 76.5%   
Share capital Rs m3,000831 361.0%   
"Free" reserves Rs m57,980155,157 37.4%   
Net worth Rs m60,980155,988 39.1%   
Long term debt Rs m15,7661,304 1,209.0%   
Total assets Rs m121,924232,253 52.5%  
Interest coverage x18.119.6 92.4%   
Debt to equity ratio x0.30 3,092.8%  
Sales to assets ratio x0.50.8 60.0%   
Return on assets %8.89.1 96.3%  
Return on equity %16.413.0 126.6%  
Return on capital %16.812.6 132.8%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50684,193 18.4%   
Fx outflow Rs m10,39939,616 26.2%   
Net fx Rs m5,10744,577 11.5%   
CASH FLOW
From Operations Rs m11,54629,841 38.7%  
From Investments Rs m-7,138-4,923 145.0%  
From Financial Activity Rs m-2,417-25,159 9.6%  
Net Cashflow Rs m2,103-266 -790.6%  

Share Holding

Indian Promoters % 40.4 25.5 158.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.4 155.6%  
FIIs % 10.7 35.3 30.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 19.9 15.3 130.1%  
Shareholders   109,995 75,885 144.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA  NOVARTIS  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 19, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS